Back to top
more

Aurinia Pharmaceuticals (AUPH)

(Real Time Quote from BATS)

$8.20 USD

8.20
831,543

-0.18 (-2.15%)

Updated Nov 13, 2024 01:34 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (61 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Aurinia (AUPH) Up 11% on Issue of New Additional Lupkynis Patent

by Zacks Equity Research

Aurinia Pharmaceuticals (AUPH) announces the issue of its new and refined method-of-use patent, supplementing its existing patent, for Lupkynis to treat lupus nephritis. Shares are up 11%.

Aurinia (AUPH) Surges 11.0%: Is This an Indication of Further Gains?

by Zacks Equity Research

Aurinia (AUPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Aurinia Pharmaceuticals (AUPH) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aurinia (AUPH) delivered earnings and revenue surprises of 30.77% and 0.16%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Ekta Bagri headshot

4 Drug, Biotech Stocks Poised to Beat Q4 Earnings Estimates

by Ekta Bagri

We look at a few drug/biotech companies, TBPH, FGEN, AUPH, CYTK, which are poised to beat on earnings in the fourth quarter.

Analysts Estimate Jazz Pharmaceuticals (JAZZ) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aurinia Pharmaceuticals (AUPH) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Aurinia (AUPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aurinia (AUPH) Soars 37.5%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Aurinia (AUPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Aurinia Pharmaceuticals (AUPH) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aurinia (AUPH) delivered earnings and revenue surprises of 66.67% and 46.35%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Aurinia (AUPH) Moves 13.1% Higher: Will This Strength Last?

by Zacks Equity Research

Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Aurinia's (AUPH) Oral Lupus Drug Lupkynis Gets European Approval

by Zacks Equity Research

Aurinia Pharmaceutical (AUPH) receives marketing authorization from the European Union for its orally administered CNI immunosuppressant, Lupkynis, for treating lupus nephritis.

Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aurinia (AUPH) delivered earnings and revenue surprises of -13.64% and 4.14%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Aurinia (AUPH) Moves 13.3% Higher: Will This Strength Last?

by Zacks Equity Research

Aurinia (AUPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aurinia (AUPH) delivered earnings and revenue surprises of -3.85% and 9.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Aurinia Pharmaceuticals (AUPH) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aurinia Pharmaceuticals (AUPH) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aurinia (AUPH) delivered earnings and revenue surprises of 3.85% and 4.34%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Aurinia Pharmaceuticals (AUPH) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options

by Zacks Equity Research

Investors need to pay close attention to CorMedix (AUPH) stock based on the movements in the options market lately.

Aurinia (AUPH) Stock Up on Potential Acquisition Rumors

by Zacks Equity Research

Aurinia (AUPH) gains on rumors of a potential acquisition yet again. Reportedly, the company is being eyed by Novartis.

Is the Options Market Predicting a Spike in Aurinia Pharmaceuticals (AUPH) Stock?

by Zacks Equity Research

Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.

Aurinia Pharmaceuticals (AUPH) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Aurinia (AUPH) delivered earnings and revenue surprises of -25.81% and -0.24%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Aurinia (AUPH) Surges 6.6%: Is This an Indication of Further Gains?

by Zacks Equity Research

Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Implied Volatility Surging for Aurinia (AUPH) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Aurinia (AUPH) stock based on the movements in the options market lately.

Aurinia (AUPH) Adds Two Candidates, Boosts Immunology Pipeline

by Zacks Equity Research

Aurinia (AUPH) acquires two pre-clinical, novel pipeline programs for the treatment of rare autoimmune, fibrotic and kidney diseases. Yet, the stock price declines.

Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.

    Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Aurinia (AUPH) delivered earnings and revenue surprises of -5.71% and 32.96%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?